MAPT and Alzheimer disease: Aducanumab was also claimed to have an effect on another hallmark of AD, decreasing the level of phosphorylated tau (p-tau) evaluated in cerebrospinal fluid (CSF) by positron emission tomography (PET) (Silvestro et al., 2022).